Aspen pockets R2bn profit as it offloads European rights to HRT drug
Aspen Pharmacare’s shares rose 2% on Monday after it announced the sale of the European rights to its menopause-treatment brand Ovestin for R3.7 billion, booking a R2 billion profit.